{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
m cidofovir
to a specific field?
Status:
US Approved Allergenic Extract
(1941)
Source:
BLA103888
(1941)
Source URL:
First approved in 1941
Source:
BLA103888
Source URL:
Class:
MIXTURE
Status:
US Previously Marketed
Source:
21 CFR 310.545(a)(12)(iv)(C) laxative:stimulant laxative aloe ingredients (aloe, aloe extract, aloe flower extract)
Source URL:
First approved in 1976
Source:
Benzoin by James Alexander Corporation
Source URL:
Class:
MIXTURE
Status:
US Previously Marketed
Source:
21 CFR 310.545(a)(20) weight control plantago seed
Source URL:
First approved in 1949
Source:
Hydrocil Instant Dietary Fiber Supplement by NUMARK BRANDS, INC
Source URL:
Class:
MIXTURE
Status:
US Previously Marketed
First approved in 1947
Class:
MIXTURE
Status:
US Previously Marketed
First marketed in 1921
Class:
MIXTURE
Status:
US Previously Marketed
Source:
aluminium magnesium silicate
(1921)
Source URL:
First marketed in 1921
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(2021)
Source URL:
First approved in 2021
Source:
21 CFR 333A
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
21 CFR 346
(2018)
Source URL:
First approved in 2017
Source:
BLA125614
Source URL:
Class:
MIXTURE
QS-21 is a purified soapbark tree (Quillaja saponaria) extract that enhances the ability of the immune system to respond to vaccine antigens. QS-21 is a promising adjuvant candidate for use in humans due to the ease of purification, its improved safety profile, and its ability to enhance cellular and humoral immunogenicity. The mechanism of action of QS-21 was speculated to be similar to QA, forming complexes with cholesterol that intercalate into the cell membrane lipids. This intercalation creates pores in the membrane to accelerate the uptake of a co-delivered antigen by the antigen presenting cells. Multiple clinical trials using QS-21 as an adjuvant, demonstrated satisfactory safety profiles and enhanced immunogenicity in immunocompromised volunteers
Status:
Possibly Marketed Outside US
Source:
NCT04590521: Phase 4 Interventional Completed HPV Infection
(2022)
Source URL:
First approved in 2017
Source:
BLA125614
Source URL:
Class:
MIXTURE
Status:
Possibly Marketed Outside US
Source:
M006
(2017)
Source URL:
First approved in 2017
Source:
M006
Source URL:
Class:
MIXTURE